Scarica l'app Stockscreener
3.31
5.08%
0.16
Dopo l'orario di chiusura:
3.26
-0.05
-1.51%
Precedente Chiudi:
$3.15
Aprire:
$3.15
Volume 24 ore:
1.13M
Relative Volume:
0.73
Capitalizzazione di mercato:
$180.12M
Reddito:
-
Utile/perdita netta:
$-297.11M
Rapporto P/E:
-0.6378
EPS:
-5.19
Flusso di cassa netto:
$-216.95M
1 W Prestazione:
+37.92%
1M Prestazione:
-32.17%
6M Prestazione:
-66.05%
1 anno Prestazione:
-65.77%
Intervallo 1D:
$3.0249
$3.34
Intervallo di 1 settimana:
$2.21
$3.78
Portata 52W:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
3.31 | 180.12M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026 - MSN
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) - MSN
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharmaceuticals (PHAT) Shares Surge After Board Member's Large Purchase - GuruFocus
Insider Buying: Asit Parikh Acquires Additional Shares of Phathom Pharmaceuticals Inc (PHAT) - GuruFocus
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target - Yahoo Finance
Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Yahoo
H.C. Wainwright cuts Phathom Pharma stock target to $20, keeps Buy rating - Investing.com Canada
Phathom Pharmaceuticals (PHAT) Price Target Lowered by Goldman Sachs | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Target Price Lowered by Guggenheim | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Tar - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Target Drops | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenhei - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenheim | PHAT Stock News - GuruFocus
PHAT Faces Price Target Cut Amidst Restructuring Efforts | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Phathom Pharmaceuticals Eyes Profitability Amid Growth - TipRanks
Phathom Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Grants 186,508 Shares Package to New Sales Chief in Strategic Hire - Stock Titan
Phathom (PHAT) Implements Strategic Shift for Long-Term Growth | - GuruFocus
Phathom Pharmaceuticals Q1 2025 Earnings: EPS Matches Estimates at -$1.18, Revenue Falls Short at $28.5 Million - GuruFocus
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Phathom Pharmaceuticals stock hits 52-week low at $3.8 By Investing.com - Investing.com India
Phathom Pharmaceuticals to Report First Quarter 2025 Financial R - GuruFocus
Phathom Pharmaceuticals stock hits 52-week low at $3.8 - Investing.com
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2025 earnings expectations - Investing.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Q1 2025 Financial Results - TradingView
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BlackRock, Inc. Reduces Stake in Phathom Pharmaceuticals Inc. - GuruFocus
Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 3,678 shares worth $16740.0. - knoxdaily.com
Uncovering the Potential of Phathom Pharmaceuticals Inc (PHAT) Stock - investchronicle.com
Upward Trajectory: Phathom Pharmaceuticals Inc (PHAT) Posts a Slidee, Closing at 4.11 - DWinneX
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting - GlobeNewswire
Groundbreaking GERD Treatment VOQUEZNA: First Real-World Data Release Coming at DDW 2025 - Stock Titan
Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday - Defense World
Phathom Pharmaceuticals Inc [PHAT] Shares Fall Approximately -55.18% Over the Year - knoxdaily.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Geode Capital Management LLC Acquires 155,577 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
SNL’s Kenan Thompson brings comedy chops to Phathom’s Voquezna campaign - Medical Marketing and Media
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 - The Manila Times
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
| Parikh Asit | Director |
Sep 10 '24 |
Option Exercise |
11.72 |
7,500 |
87,900 |
93,000 |
| Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
| Henderson Molly | CFO and CBO |
Jan 21 '25 |
Sale |
6.59 |
6,583 |
43,371 |
93,546 |
| Nabulsi Azmi | Chief Operating Officer |
Jan 21 '25 |
Sale |
6.59 |
7,886 |
51,957 |
233,390 |
| Curran Terrie | President and Chief Executive |
Jan 21 '25 |
Sale |
6.59 |
19,109 |
125,884 |
360,465 |
| Nabulsi Azmi | Chief Operating Officer |
Dec 19 '24 |
Sale |
8.00 |
1,118 |
8,944 |
239,303 |
| Henderson Molly | CFO and CBO |
Dec 19 '24 |
Sale |
8.00 |
1,291 |
10,328 |
98,156 |
| KARBE FRANK | Director |
Dec 13 '24 |
Buy |
7.93 |
12,500 |
99,084 |
57,000 |
4.19%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):